2024
High-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional series
Epperla N, Zayac A, Landsburg D, Bock A, Nowakowski G, Ayers E, Girton M, Hu M, Beckman A, Li S, Medeiros L, Chang J, Kurt H, Sandoval-Sus J, Ansari-Lari M, Kothari S, Kress A, Xu M, Torka P, Sundaram S, Smith S, Naresh K, Karimi Y, Bond D, Evens A, Naik S, Kamdar M, Haverkos B, Karmali R, Farooq U, Vose J, Rubinstein P, Chaudhry A, Olszewski A. High-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional series. Blood Advances 2024, 8: 5355-5364. PMID: 39189932, PMCID: PMC11568788, DOI: 10.1182/bloodadvances.2024013791.Peer-Reviewed Original ResearchBaseline CNS involvementCentral nervous system recurrenceHigh-grade B-cell lymphomaCentral nervous systemB-cell lymphomaCNS involvementCNS recurrenceIncidence of CNS recurrenceRisk of CNS recurrenceCentral nervous system involvementMulti-institutional seriesNon-GCB subtypeBone marrow involvementMulticenter retrospective studyCNS-IPIRisk factor analysisMarrow involvementMYC rearrangementNon-GCBPrimary therapyCD5 expressionAutologous transplantationSurvival outcomesNo significant differenceNOS patients
2023
IRF8 may be a useful marker for blastic plasmacytoid dendritic cell neoplasm, especially with weak CD123 expression
Tang H, Panse G, Braddock D, Perincheri S, Xu M, McNiff J. IRF8 may be a useful marker for blastic plasmacytoid dendritic cell neoplasm, especially with weak CD123 expression. Journal Of Cutaneous Pathology 2023, 50: 595-600. PMID: 37082914, DOI: 10.1111/cup.14439.Peer-Reviewed Original ResearchConceptsBlastic plasmacytoid dendritic cell neoplasmPlasmacytoid dendritic cell neoplasmDendritic cell neoplasmPunch biopsy specimenBiopsy specimenCell neoplasmsCase of BPDCNUseful markerTumor cellsTCL-1 expressionAtypical mononuclear cellsBone marrow involvementDiffuse dermal infiltrateDendritic cell lineagePotential diagnostic pitfallRegulatory factor 8TCL-1BPDCN casesCD123 expressionMarrow involvementDermal infiltrateCutaneous nodulesMyelodysplastic syndromeSkin nodulesMononuclear cells
2022
Peripheral Blood Involvement at Staging in Patients With Aggressive Peripheral T-Cell Lymphoma
Avery J, Chandhok N, Rainey C, Torres R, Huntington S, Isufi I, Seropian S, Xu ML, Foss F. Peripheral Blood Involvement at Staging in Patients With Aggressive Peripheral T-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2022, 22: 680-689. PMID: 35568635, DOI: 10.1016/j.clml.2022.04.019.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaT-cell lymphomaBone marrow involvementBlood involvementFlow cytometryMarrow involvementNodal subtypesAggressive peripheral T-cell lymphomaNodal T-cell lymphomasNegative flow cytometryPeripheral blood involvementPositive flow cytometryMalignant T cellsMalignant tumor cellsMedian PFSTime ofdiagnosisOverall survivalLymph nodesPoor outcomeDisease stagePeripheral bloodT cellsPrognostic measuresRare subgroupLymphoma
2020
Cutaneous Involvement in Plasma Cell Myeloma
Panse G, Subtil A, McNiff JM, Glusac EJ, Ko CJ, Galan A, Myung P, Xu ML. Cutaneous Involvement in Plasma Cell Myeloma. American Journal Of Clinical Pathology 2020, 155: 106-116. PMID: 32885235, DOI: 10.1093/ajcp/aqaa122.Peer-Reviewed Original ResearchConceptsPlasma cell myelomaCutaneous involvementSquamous cell carcinomaAmyloid depositionCell carcinomaCell myelomaCases of PCMBone marrow involvementCyclin D1 immunoreactivityDisease-related deathLight chain restrictionCCND1 gene rearrangementMarrow involvementSkin involvementClinicopathologic featuresCytomorphologic spectrumCutaneous lesionsPoor outcomeCommon immunophenotypeChain restrictionClinical dataCytogenetic findingsOlder individualsGene rearrangementsMyeloma
2019
Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell Transplantation
Chandhok N, Huntington S, Isufi I, Gowda L, Xu M, Bar N, Seropian S, Foss F. Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell Transplantation. Blood 2019, 134: 4055. DOI: 10.1182/blood-2019-128888.Peer-Reviewed Original ResearchAutologous stem cell transplantationAggressive T-cell lymphomaProgression-free survivalT-cell lymphomaTime of diagnosisPeripheral blood involvementBone marrow involvementStem cell transplantationMedian progression-free survivalOverall survivalCell lymphomaBlood involvementFirst remissionMarrow involvementPrognostic factorsCell transplantationFlow cytometryPeripheral bloodWorse outcomesPositive groupNegative groupExtranodal natural killer T-cell lymphomaBone marrowFront autologous stem cell transplantationNatural killer T-cell lymphoma
2018
Hepatosplenic T-Cell Lymphomas
Gowda L, Foss F. Hepatosplenic T-Cell Lymphomas. Cancer Treatment And Research 2018, 176: 185-193. PMID: 30596219, DOI: 10.1007/978-3-319-99716-2_9.Peer-Reviewed Original ResearchConceptsHepatosplenic T-cell lymphomaT-cell lymphomaPeripheral T-cell lymphomaHematopoietic stem cell transplantExtranodal peripheral T-cell lymphomaLimited salvage optionsYear of diagnosisAggressive disease courseBone marrow involvementStem cell transplantEligible patientsMarrow involvementPerformance statusPost chemotherapyDisease courseImmune dysregulationProlong remissionSalvage optionCell transplantClinical manifestationsTherapeutic armamentariumLethal outcomeAggressive phenotypeFourth decadeModest response
2014
Impact of velaglucerase alfa on bone marrow burden score in adult patients with type 1 Gaucher disease: 7-Year follow-up
Elstein D, Haims AH, Zahrieh D, Cohn GM, Zimran A. Impact of velaglucerase alfa on bone marrow burden score in adult patients with type 1 Gaucher disease: 7-Year follow-up. Blood Cells Molecules And Diseases 2014, 53: 56-60. PMID: 24581483, DOI: 10.1016/j.bcmd.2014.02.006.Peer-Reviewed Original ResearchConceptsBone marrow burdenBMB scoreVelaglucerase alfaLumbar spinePhase I/II trialLong-term extension studyGaucher diseaseType 1 Gaucher diseaseTotal score decreaseBone marrow infiltrationBone marrow burden scoreT2-weighted magnetic resonance imagesAssessable patientsII trialAdult patientsMarrow involvementMarrow infiltrationProspective studyBurden scoreGD patientsMedian changeLarge cohortScore decreaseDose reductionPatients
2010
Bone marrow involvement in patients with posttransplant lymphoproliferative disorders: incidence and prognostic factors
Montanari F, O'Connor OA, Savage DG, Zain JM, Venkatraman S, McCormick EK, Crook MT, Tsao L, Sevilla DW, Bhagat G, Alobeid B. Bone marrow involvement in patients with posttransplant lymphoproliferative disorders: incidence and prognostic factors. Human Pathology 2010, 41: 1150-1158. PMID: 20381113, DOI: 10.1016/j.humpath.2009.11.016.Peer-Reviewed Original ResearchConceptsMonomorphic posttransplant lymphoproliferative disorderPosttransplant lymphoproliferative disorderBone marrow involvementPolymorphic posttransplant lymphoproliferative disordersDiffuse large B-cell lymphomaLarge B-cell lymphomaMarrow involvementLymphoproliferative disordersB-cell lymphomaSerologic parametersEpstein-Barr virus statusPosttransplant lymphoproliferative disorder patientsDe novo diffuse large B-cell lymphomaNovo diffuse large B-cell lymphomaBone marrow examinationElevated lactate dehydrogenaseBone marrow biopsyHodgkin lymphoma typeDiffuse large B-cell lymphoma casesLarge B-cell lymphoma casesB-cell lymphoma casesSensitive screening toolStaging biopsiesExtranodal involvementMarrow examination
2007
Bone Marrow Contributes to Epithelial Cancers in Mice and Humans as Developmental Mimicry
Cogle CR, Theise ND, Fu D, Ucar D, Lee S, Guthrie SM, Lonergan J, Rybka W, Krause DS, Scott EW. Bone Marrow Contributes to Epithelial Cancers in Mice and Humans as Developmental Mimicry. Stem Cells 2007, 25: 1881-1887. PMID: 17478582, DOI: 10.1634/stemcells.2007-0163.Peer-Reviewed Original ResearchConceptsEpithelial cancersEpithelial neoplasiaHematopoietic stem cellsNeoplastic environmentStem cellsHematopoietic cell transplantationBone marrow cellsHuman marrowMarrow involvementMarrow cellsSmall bowelCell transplantationLung neoplasiaMouse modelBone marrowMimicryDistant organsNeoplasiaCancerMarrowStable fusionCellsPhenotypeInductionBowel
2006
Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT
Arcaini L, Burcheri S, Rossi A, Paulli M, Bruno R, Passamonti F, Brusamolino E, Molteni A, Pulsoni A, Cox M, Orsucci L, Fabbri A, Frezzato M, Voso M, Zaja F, Montanari F, Merli M, Pascutto C, Morra E, Cortelazzo S, Lazzarino M. Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT. Annals Of Oncology 2006, 18: 346-350. PMID: 17071937, DOI: 10.1093/annonc/mdl388.Peer-Reviewed Original ResearchConceptsHCV-positive patientsMarginal zone B-cell lymphomaHCV-negative patientsEvent-free survivalHCV infectionMarginal zone lymphomaB-cell lymphomaOverall survivalHigh prevalenceMost HCV-positive patientsHepatitis C virus infectionC virus infectionBone marrow involvementOverall response rateMALT sitesHCV serostatusAdvanced diseasePresenting featuresHCV serologyMarrow involvementOrgan involvementPoor OSAntiviral treatmentIndolent courseHistological diagnosisNongastric Marginal-Zone B-Cell MALT Lymphoma: Prognostic Value of Disease Dissemination
Arcaini L, Burcheri S, Rossi A, Passamonti F, Paulli M, Boveri E, Brusamolino E, Orlandi E, Molteni A, Pulsoni A, Cox MC, Orsucci L, Fabbri A, Frezzato M, Voso MT, Zaja F, Montanari F, Pascutto C, Morra E, Cortelazzo S, Lazzarino M. Nongastric Marginal-Zone B-Cell MALT Lymphoma: Prognostic Value of Disease Dissemination. The Oncologist 2006, 11: 285-291. PMID: 16549813, DOI: 10.1634/theoncologist.11-3-285.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnthracyclinesAntibodies, MonoclonalAntigens, CD20Antineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBone Marrow NeoplasmsChemotherapy, AdjuvantFemaleFollow-Up StudiesHumansItalyLymphatic MetastasisLymphoma, B-Cell, Marginal ZoneMaleMiddle AgedMultivariate AnalysisPrognosisRadiotherapy, AdjuvantRetrospective StudiesConceptsBone marrow involvementMarrow involvementNodal involvementClinical featuresSurvival timeBone marrowMedian event-free survival timeB-cell MALT lymphomaMedian overall survival timeDisease disseminationEvent-free survival timeB-cell mucosaStage IV diseaseOverall survival timeLymphoid tissue lymphomaMarginal zone lymphomaLonger EFSNodal diseaseShorter OSOS timeTissue lymphomaWaldeyer's ringPoor outcomePrognostic significancePrognostic value
1998
Morphologic, Immunophenotypic, and Molecular Evaluation of Bone Marrow Involvement in Non-Hodgkin's Lymphoma
Crotty P, Smith B, Tallini G. Morphologic, Immunophenotypic, and Molecular Evaluation of Bone Marrow Involvement in Non-Hodgkin's Lymphoma. Applied Immunohistochemistry & Molecular Morphology 1998, 7: 90-95. PMID: 9785007, DOI: 10.1097/00019606-199804000-00005.Peer-Reviewed Original ResearchMeSH KeywordsAntigens, CDBiomarkers, TumorBone MarrowBone Marrow ExaminationClone CellsFlow CytometryGene Rearrangement, B-LymphocyteGene Rearrangement, T-LymphocyteHumansImmunophenotypingLymphoma, B-CellLymphoma, Non-HodgkinLymphoma, T-CellNeoplasm ProteinsNeoplastic Stem CellsPolymerase Chain ReactionSensitivity and SpecificityConceptsPrimer polymerase chain reactionMarrow involvementT-cell neoplasiaFlow cytometryB-cell neoplasiaObjective evidenceT-cell receptor gene rearrangementsBone marrow involvementConsensus primer polymerase chain reactionNon-Hodgkin lymphomaChronic lymphocytic leukemiaB-cell lymphomaT-cell neoplasmsB-cell neoplasmsReceptor gene rearrangementsDetection of clonalityDetectable diseaseHodgkin's lymphomaPolymerase chain reactionLymphocytic leukemiaApparent diseaseLymphomaPatientsImportant adjunctNeoplasia
1986
Prognostic indicators in diffuse large-cell (histiocytic) lymphoma
Todd M, Portlock C, Farber L, Holford T, Bertino J. Prognostic indicators in diffuse large-cell (histiocytic) lymphoma. International Journal Of Radiation Oncology • Biology • Physics 1986, 12: 593-601. PMID: 2422144, DOI: 10.1016/0360-3016(86)90068-4.Peer-Reviewed Original ResearchConceptsDiffuse large cell lymphomaLarge cell lymphomaPrognostic groupsSystemic symptomsPrognostic indicatorAnn Arbor staging systemBone marrow involvementBulk of diseaseLactic dehydrogenaseDiffuse histiocytic lymphomaAnn Arbor classificationStage of diseaseReliable prognostic indicatorChemotherapy clinical trialsLukes-Collins classificationSerum lactic dehydrogenaseMarrow involvementOverall survivalCombination chemotherapyPrognostic factorsDisease involvementPathological criteriaStaging systemSpecific therapyHistiocytic lymphoma
1984
Prolonged initial remission in patients with nodular mixed lymphoma.
Longo D, Young R, Hubbard S, Wesley M, Fisher R, Jaffe E, Berard C, DeVita V. Prolonged initial remission in patients with nodular mixed lymphoma. Annals Of Internal Medicine 1984, 100: 651-6. PMID: 6370065, DOI: 10.7326/0003-4819-100-5-651.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyCyclophosphamideDoxorubicinEtoposideFemaleHumansLeucovorinLymphoma, FollicularMaleMechlorethamineMethotrexateMiddle AgedNeoplasm StagingPrednisoneProcarbazinePrognosisRetrospective StudiesTime FactorsVincristineConceptsNodular mixed lymphomaComplete response rateMixed lymphomaComplete respondersInitial remissionMedian survivalResponse rateOverall complete response ratePrimary treatment regimensBone marrow involvementLactate dehydrogenase levelsNational Cancer InstituteAverage remissionB symptomsComplete remissionFirst remissionMarrow involvementShorter survivalTreatment regimensDehydrogenase levelsRemissionPatientsStage ICancer InstituteLymphoma
1981
Factors predicting long-term survival in diffuse mixed, histiocytic, or undifferentiated lymphoma.
Fisher R, Hubbard S, DeVita V, Berard C, Wesley R, Cossman J, Young R. Factors predicting long-term survival in diffuse mixed, histiocytic, or undifferentiated lymphoma. Blood 1981, 58: 45-51. PMID: 7236892, DOI: 10.1182/blood.v58.1.45.bloodjournal58145.Peer-Reviewed Original ResearchConceptsLong-term survivalHuge abdominal massGastrointestinal involvementAbdominal massCurrent therapiesExcellent long-term survivalBone marrow statusBone marrow involvementSubset of patientsCases of diffuseMarrow statusConstitutional symptomsMarrow involvementMedian survivalHepatic involvementPrognostic factorsClinical factorsUndifferentiated lymphomaMale sexPatient survivalSerum LDHHistopathologic materialPatient groupPoor prognosisClinical trialsFactors Predicting Long-Term Survival in Diffuse Mixed, Histiocytic, or Undifferentiated Lymphoma
Fisher R, Hubbard S, DeVita V, Berard C, Wesley R, Cossman J, Young R. Factors Predicting Long-Term Survival in Diffuse Mixed, Histiocytic, or Undifferentiated Lymphoma. Blood 1981, 58: 45-51. DOI: 10.1182/blood.v58.1.45.45.Peer-Reviewed Original ResearchLong-term survivalHuge abdominal massGastrointestinal involvementAbdominal massCurrent therapiesPredicting Long-Term SurvivalExcellent long-term survivalBone marrow statusBone marrow involvementSubset of patientsCases of diffuseMarrow statusConstitutional symptomsMarrow involvementMedian survivalHepatic involvementPrognostic factorsClinical factorsUndifferentiated lymphomaMale sexPatient survivalSerum LDHHistopathologic materialPatient groupPoor prognosis
1979
Central nervous system complications of non-Hodgkin's lymphoma The potential role for prophylactic therapy
Young R, Howser D, Anderson T, Fisher R, Jaffe E, DeVita V. Central nervous system complications of non-Hodgkin's lymphoma The potential role for prophylactic therapy. The American Journal Of Medicine 1979, 66: 435-443. PMID: 433950, DOI: 10.1016/0002-9343(79)91065-9.Peer-Reviewed Original ResearchConceptsCentral nervous systemCNS diseaseHodgkin's lymphomaCentral nervous system complicationsNervous system complicationsWhole-brain irradiationGood clinical responseBone marrow involvementTime of diagnosisGroup of patientsAdvanced diseaseBrain irradiationClinical remissionCNS prophylaxisIntrathecal chemotherapyLymphomatous meningitisProphylactic therapyClinical responseMarrow involvementPositive cytologyMalignant lymphomaSystem complicationsLumbar punctureNodular lymphomaRisk factors
1976
Central nervous system complications in patients with diffuse histiocytic and undifferentiated lymphoma: leukemia revisited.
Bunn P, Schein P, Banks P, DeVita V. Central nervous system complications in patients with diffuse histiocytic and undifferentiated lymphoma: leukemia revisited. Blood 1976, 47: 3-10. PMID: 1106798, DOI: 10.1182/blood.v47.1.3.bloodjournal4713.Peer-Reviewed Original ResearchConceptsLeptomeningeal lymphomaCentral nervous systemHistologic types of non-Hodgkin's lymphomasProgression of systemic diseaseCentral nervous system complicationsCentral nervous system therapyProphylactic CNS therapySite of relapseBone marrow involvementNon-Hodgkin's lymphomaIntrathecal drug administrationPatient's clinical courseCerebrospinal fluid cytologyResponse to therapyNervous system complicationsNervous system therapyBone marrow cavityUndifferentiated lymphomaMarrow involvementClinical remissionSystemic therapyCNS therapyClinical courseHistological typeSystemic complicationsCentral Nervous System Complications in Patients With Diffuse Histiocytic and Undifferentiated Lymphoma: Leukemia Revisited
Bunn P, Schein P, Banks P, DeVita V. Central Nervous System Complications in Patients With Diffuse Histiocytic and Undifferentiated Lymphoma: Leukemia Revisited. Blood 1976, 47: 3-10. DOI: 10.1182/blood.v47.1.3.3.Peer-Reviewed Original ResearchLeptomeningeal lymphomaCentral nervous systemHistologic types of non-Hodgkin's lymphomasProgression of systemic diseaseCentral nervous system complicationsCentral nervous system therapyProphylactic CNS therapySite of relapseBone marrow involvementNon-Hodgkin's lymphomaIntrathecal drug administrationPatient's clinical courseCerebrospinal fluid cytologyResponse to therapyNervous system complicationsNervous system therapyBone marrow cavityUndifferentiated lymphomaMarrow involvementClinical remissionSystemic therapyCNS therapyClinical courseHistological typeSystemic complications
1975
American Burkitt's lymphoma: A clinicopathologic study of 30 cases II. Pathologic correlations
Banks P, Arseneau J, Gralnick H, Canellos G, DeVita V, Berard C. American Burkitt's lymphoma: A clinicopathologic study of 30 cases II. Pathologic correlations. The American Journal Of Medicine 1975, 58: 322-329. PMID: 163581, DOI: 10.1016/0002-9343(75)90598-7.Peer-Reviewed Original ResearchMeSH KeywordsAbdomenAdolescentAdultAutopsyBiopsyBone MarrowBurkitt LymphomaChildChild, PreschoolCytoplasmFemaleHumansInclusion BodiesIntestinal NeoplasmsIntestine, SmallLiverLymphatic MetastasisMacrophagesMaleMandibular NeoplasmsMaxillary NeoplasmsNorth AmericaOvarian NeoplasmsSouth AmericaUnited StatesConceptsMonths of therapyBone marrow involvementOlder median ageCentral nervous systemInitial therapyClinicopathologic studyMarrow involvementBurkitt's typeMedian ageMultiorgan involvementMalignant lymphomaShorter survivalMassive infiltrationAmerican patientsPelvic sitesPathologic correlationDiffuse necrosisHistologic appearanceTherapeutic implicationsOrgan sitesBone marrowNervous systemEndemic regionsTumor cellsLymphoma
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply